Yes, polatuzumab vedotin causes neutropenia
Polatuzumab vedotin definitively causes neutropenia, with Grade 3-4 neutropenia occurring in 35-61% of patients depending on the treatment regimen used. This is a well-established and common hematologic toxicity that requires proactive monitoring and management.
Evidence from FDA Drug Label and Guidelines
The FDA label explicitly addresses neutropenia as a significant adverse event requiring dose modifications 1. When Grade 3-4 neutropenia occurs, the label mandates holding all treatment until absolute neutrophil count (ANC) recovers to >1,000/microliter, with specific algorithms for resumption based on timing of recovery 1.
The 2025 NCCN Guidelines document neutropenia rates across multiple polatuzumab-containing regimens 2:
- Mosunetuzumab + Polatuzumab vedotin: 35% neutropenia rate
- Polatuzumab vedotin in Pola-R-CHP regimen: Neutropenia is a common treatment-emergent adverse event
Real-World and Clinical Trial Data
The pivotal randomized trial comparing polatuzumab vedotin with bendamustine and rituximab (Pola-BR) versus BR alone showed Grade 3-4 neutropenia in 46.2% of Pola-BR patients versus 33.3% in the BR-only group 3. This demonstrates that polatuzumab vedotin adds meaningful neutropenic risk beyond the chemotherapy backbone alone.
Real-world studies consistently confirm these findings:
- Turkish cohort: Grade 3-4 neutropenia was among the most common hematological toxicities 4
- Korean real-world data: Grade 3-4 hematologic toxicities occurred in 92.3% of salvage patients and 100% of post-CAR T patients 5
- Japanese multicenter study: Lymphocytopenia (Grade 3-4) occurred in 82% of patients, with only 36% completing six cycles due to toxicity 6
A study combining polatuzumab with rituximab and lenalidomide showed Grade 3-4 neutropenia in 61% of patients (35 of 57), making it the most common severe adverse event 7.
Clinical Management Implications
The FDA label recommends prophylactic G-CSF for patients receiving Pola-BR 1. This is particularly important given that:
- Neutropenia can delay treatment cycles
- Only 36-60% of patients complete all six planned cycles in real-world settings due to toxicity 6
- The bridging therapy group (pre-CAR T) showed lower rates of Grade 3-4 hematologic toxicity (46.2%) compared to salvage or post-CAR T settings (92-100%) 5
Key monitoring points:
- Check ANC before each cycle
- If ANC <1,000/microliter, hold treatment
- Consider G-CSF prophylaxis for all subsequent cycles after first neutropenic event
- If recovery takes >7 days, consider bendamustine dose reduction first, then polatuzumab dose reduction to 1.4 mg/kg if needed 1
The neutropenia risk is dose-dependent and regimen-dependent, but it is an expected and manageable toxicity that should not preclude use of this effective therapy in appropriate patients with relapsed/refractory DLBCL.